These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 483271)

  • 41. Analysis of coagulation and fibrinolysis after intravenous anisoylated plasminogen streptokinase activator complex or heparin in patients with acute myocardial infarction. A Belgian multicentre study.
    Renkin J; Beys CC; Lavenne-Pardonge E; Pintens H; Col J
    Drugs; 1987; 33 Suppl 3():253-60. PubMed ID: 3315603
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Results of streptokinase-plasminogen therapy in deep venous thrombosis].
    Trübestein G; Ludwig M; Etzel E
    Med Welt; 1983 Apr; 34(14):448-51. PubMed ID: 6855550
    [No Abstract]   [Full Text] [Related]  

  • 43. Rapid dissociation of platelet-rich fibrin clots in vitro by a combination of plasminogen activators and antiplatelet agents.
    Lam SC; Dieter JP; Strebel LC; Taylor TM; Muscolino G; Feinberg H; Le Breton GC
    J Pharmacol Exp Ther; 1991 Dec; 259(3):1371-8. PubMed ID: 1762085
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Fibrinolytic therapy of deep venous thrombosis. Streptokinase, urokinase, plasminogen substitution].
    Theiss W; Kriessmann A; Wirtzfeld A
    Dtsch Med Wochenschr; 1980 Feb; 105(8):243-6. PubMed ID: 6986252
    [No Abstract]   [Full Text] [Related]  

  • 45. The conversion of streptokinase-plasminogen complex to SK-plasmin complex in the presence of fibrin or fibrinogen.
    Takada Y; Takada A
    Thromb Res; 1989 Apr; 54(2):133-9. PubMed ID: 2526391
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Systemic effects of anisoylated plasminogen streptokinase activator complex and streptokinase therapy in acute myocardial infarction. Coagulation aspects of the Dutch Invasive Reperfusion Study.
    Hoffmann JJ; Bonnier JJ; de Swart JB; Custers P; Vijgen M
    Drugs; 1987; 33 Suppl 3():242-6. PubMed ID: 3315602
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dissolution of thrombi by tissue plasminogen activator, urokinase and streptokinase in an artificial circulating system.
    Mattsson C; Nyberg-Arrhenius V; Wallén P
    Thromb Res; 1981 Mar; 21(6):535-45. PubMed ID: 7022741
    [No Abstract]   [Full Text] [Related]  

  • 48. Release of fibrinolytic enzymes by macrophages in response to soluble fibrin.
    Sherman LA; Lee JL; Stewart CC
    J Reticuloendothel Soc; 1981 Nov; 30(5):317-29. PubMed ID: 7198690
    [No Abstract]   [Full Text] [Related]  

  • 49. Evidence for a sustained fibrinolytic response to anisoylated plasminogen streptokinase activator complex in vitro.
    Fears R
    Drugs; 1987; 33 Suppl 3():83-7. PubMed ID: 3315617
    [No Abstract]   [Full Text] [Related]  

  • 50. Proteolysis of fibrinogen in healthy volunteers following major and minor vivo plasminogen activation.
    Prowse CV; Dawes J; Lane DA; Ireland H; Knight I
    Thromb Res; 1982 Jul; 27(1):91-7. PubMed ID: 6750837
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of streptokinase on fibrinogen and related proteins in plasma.
    Bowie LJ; Kinney R; Vye M; Eckert B; Kwaan HC
    Clin Chem; 1986 Jan; 32(1 Pt 1):67-70. PubMed ID: 3940737
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A STANDARD CLOT METHOD FOR THE ASSAY OF PLASMINOGEN ACTIVATORS, ANTI-ACTIVATORS, AND PLASMIN.
    HAWKEY CM; STAFFORD JL
    J Clin Pathol; 1964 Mar; 17(2):175-81. PubMed ID: 14149945
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Late lysis of venous thromboses].
    Tilsner V
    Vasa; 1974; 3(4):458-60. PubMed ID: 4440227
    [No Abstract]   [Full Text] [Related]  

  • 54. [Biological surveillance of streptokinase treatment].
    Juhan I; Sampol J; Léonetti J; Mathieu P; Muratore R; Serradimigni A
    Coeur Med Interne; 1978; 17(1):49-55. PubMed ID: 639488
    [No Abstract]   [Full Text] [Related]  

  • 55. Mechanism of inhibition of fibrinolysis and fibrinogenolysis by the end fibrinogen degradation products.
    Khavkina LS; Rozenfeld MA; Leonova VB
    Thromb Res; 1995 Apr; 78(2):173-87. PubMed ID: 7482434
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Biochemical characteristics of fibrolase, a fibrinolytic protease from snake venom.
    Ahmed NK; Tennant KD; Markland FS; Lacz JP
    Haemostasis; 1990; 20(3):147-54. PubMed ID: 1696922
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Treatment of deep-vein thrombosis with intermittent streptokinase and plasminogen infusion.
    Kakkar VV; Sagar S; Lewis M
    Lancet; 1975 Oct; 2(7937):674-6. PubMed ID: 52050
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Fibrin clot structure - pro-fibrinolytic effect of oral contraceptives in apparently healthy women.
    Sidelmann JJ; Kluft C; Krug AH; Winkler U; Jespersen J; Gram JB
    Thromb Haemost; 2017 Apr; 117(4):700-705. PubMed ID: 28150855
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Biochemical aspects of the streptokinase effect].
    Landmann H
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1976; 103(3):437-44. PubMed ID: 63431
    [No Abstract]   [Full Text] [Related]  

  • 60. On the binding of native plasminogen to fibrin and its role in thrombolysis.
    Shah GA; Dhall DP
    Thromb Res; 1983 Oct; 32(1):67-72. PubMed ID: 6658707
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.